Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Thyroid Neoplasms 1Skin Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

Cyclophosphamide 21fludarabine phosphate 18Whole-Body Irradiation 17Methotrexate 17Tacrolimus 15Peripheral Blood Stem Cell Transplantation 15Mycophenolic Acid 13Dexamethasone 11Vincristine 10Etoposide 10Antilymphocyte Serum 10Calcium Dobesilate 9Busulfan 9Rituximab 8Doxorubicin 8merphos 7Filgrastim 7Cytarabine 7Sirolimus 6Prednisone 6Melphalan 6Granulocyte Colony-Stimulating Factor 6Cyclosporine 6pegaspargase 5dexamethasone acetate 5dexamethasone 21-phosphate 5prednylidene 4deltacortene 4auricularum 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Interleukin-15 × Clear all
NCT04185220 2023-01-04

Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
6 enrolled 16 charts
LymphoidOther hematologic neoplasm

Mycosis Fungoides, Sezary Syndrome, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡